Identification and characterization of cytochrome P4502D6*56B (CYP2D6*56B), a novel allele associated with the poor metabolizer phenotype.

被引:0
作者
Gaedigk, A. [1 ]
Eklund, J. D. [1 ]
Pearce, R. E. [1 ]
Leeder, J. S. [1 ]
Alander, S. W. [1 ]
Bradford, L. D. [1 ]
Kennedy, M. J. [1 ]
机构
[1] Univ Louisville, Childrens Mercy Hosp, Morehouse Sch Med, Kansas City, MO USA
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:S85 / S85
页数:1
相关论文
共 50 条
[31]   Therapeutic Drug Monitoring of Psychotropics as a Diagnostic Tool for CYP2D6 Poor Metabolizer Phenotype [J].
Ganesh, Soraya, V ;
Beunk, Lianne ;
Nikolik, Bojan ;
van der Weide, Jan ;
Bet, Pierre M. .
THERAPEUTIC DRUG MONITORING, 2021, 43 (05) :672-680
[32]   Correlation between cytochrome P-450CYP2D6 CYP2D6) genotype and phenotype [J].
Chen, SQ ;
Wedlund, PJ .
ACTA PHARMACOLOGICA SINICA, 1999, 20 (07) :585-588
[33]   Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test [J].
Laine, K ;
Tybring, G ;
Härtter, S ;
Andersson, K ;
Svensson, JO ;
Widén, J ;
Bertilsson, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (04) :327-335
[34]   FREQUENCY OF A SPECIFIC CYTOCHROME P4502D6B (CYP2D6B) MUTANT ALLELE IN CLINICALLY DIFFERENTIATED GROUPS OF PATIENTS WITH PARKINSON DISEASE [J].
AKHMEDOVA, SN ;
PUSHNOVA, EA ;
YAKIMOVSKY, AF ;
AVTONOMOV, VV ;
SCHWARTZ, EI .
BIOCHEMICAL AND MOLECULAR MEDICINE, 1995, 54 (02) :88-90
[35]   Heterozygosity for the most common poor metabolizer allele (CYP2D6*4) was not associated with increased susceptibility to ankylosing spondylitis (AS) [J].
Marzouk, K. ;
Pope, A. ;
Hamilton, S. ;
Rahman, P. ;
Peddle, L. .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 :405-405
[36]   Functional Characterization of Cytochrome P450 2D6 (CYP2D6) Allelic Variant CYP2D6*10 [J].
Dong, A. N. ;
Ong, C. E. ;
Pan, Y. ;
Palanisamy, U. D. ;
Ismail, R. .
PUBLIC HEALTH GENOMICS, 2015, 18 :49-49
[37]   IDENTIFICATION OF A NEW VARIANT CYP2D6 ALLELE WITH A SINGLE-BASE DELETION IN EXON-3 AND ITS ASSOCIATION WITH THE POOR METABOLIZER PHENOTYPE [J].
SAXENA, R ;
SHAW, GL ;
RELLING, MV ;
FRAME, JN ;
MOIR, DT ;
EVANS, WE ;
CAPORASO, N ;
WEIFFENBACH, B .
HUMAN MOLECULAR GENETICS, 1994, 3 (06) :923-926
[38]   The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes - Independent commentary [J].
Brosen, K .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (07) :S749-S750
[39]   Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype [J].
Martinez de Duenas, Eduardo ;
Ochoa Aranda, Enrique ;
Blancas Lopez-Barajas, Isabel ;
Ferrer Magdalena, Teresa ;
Bandres Moya, Fernando ;
Chicharro Garcia, Luis Miguel ;
Gomez Capilla, Jose A. ;
Zafra Ceres, Mercedes ;
de Haro, Tomas ;
Romero Llorens, Regina ;
Ferrer Albiach, Carlos ;
Ferriols Lisart, Rafael ;
Chover Lara, Dolores ;
Lopez Rodriguez, Angela ;
Munarriz Ferrandis, Javier ;
Olmos Anton, Santiago .
BREAST, 2014, 23 (04) :400-406
[40]   CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment [J].
Almoguera, Berta ;
Riveiro-Alvarez, Rosa ;
Lopez-Castroman, Jorge ;
Dorado, Pedro ;
Vaquero-Lorenzo, Concepcion ;
Fernandez-Piqueras, Jose ;
LLerena, Adrian ;
Abad-Santos, Francisco ;
Baca-Garcia, Enrique ;
Dal-Re, Rafael ;
Ayuso, Carmen .
PHARMACOGENETICS AND GENOMICS, 2013, 23 (11) :627-630